43results about How to "Prevention or treatment" patented technology

An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof. In the general formula (I), R¹ and R² represent hydrogen atoms, and the like; R³ represents a hydrogen atom, and the like; X, Y, and Z represent nitrogen atoms, and the like; A represents a phenylene group, and the like; n represents 1 or 2, and the like; and V and W represent oxygen atoms, and the like.

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Disclosed herein are a new phenylacetate derivative represented by Chemical Formula 1 or pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for prevention or treatment of diseases induced by the activation of T-type calcium ion channels containing the same. The composition containing the phenylacetate derivative according to the present invention effectively inhibits the activation of T-type calcium ion channels and may be useful in the prevention or treatment of diseases such as hypertension, cancer, epilepsy, and neurogenic pains induced by the activation of T-type calcium ion channels.

Low molecular weight compound exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof:

Disclosed are N-{[(1R,4S,6R)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

A nutritional composition for the treatment of syndromes related to dysfunctional energy metabolism is provided. The composition comprises a combination of L-carnitine, acetyl-L-carnitine, pantothenate and niacinamide. Methods of treatment of dysfunctional energy metabolism are also disclosed.

The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.

Compounds exhibiting an osteogenesis-promoting action having the general formula (I) or a pharmacologically acceptable salt thereof:

An anti-obesity agent or a glucose tolerance-ameliorating agent containing a bacterium belonging to the genus Bifidobacterium as an active ingredient, wherein the bacterium belonging to the genus Bifidobacterium exhibits a conversion rate from linoleic acid into conjugated linoleic acid of not more than 10%. The present invention is able to provide an anti-obesity agent and a glucose tolerance-ameliorating agent that are effective for the prevention or treatment of obesity or the amelioration of glucose tolerance and also exhibit superior safety, as well as providing foods or beverages containing these agents. Further, the present invention is also able to provide a bacterium of the genus Bifidobacterium, and in particular a Bifidobacterium breve, that is effective for the prevention or treatment of obesity or the amelioration of glucose tolerance and also exhibits superior safety, as well as providing a pharmaceutical composition containing this bacterium.

The present invention relates to use of ginsenoside Rg3, Rg5 or Rk1, or extract of ginseng, red ginseng or processed ginseng comprising the ginsenosides; a composition for preventing or treating angiostenosis and restenosis comprising the ginsenosides or extracts; a method for preventing or treating angiostenosis and restenosis by administrating the ginsenosides or extracts comprising the ginsenosides; and a preparation method of agents for preventing or treating angiostenosis and restenosis. The present composition can effectively prevent or treat angiostenosis and restenosis.

Disclosed are N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

A method for treatment or prevention of oral cavity diseases and disorders and/or related states, in a subject in need of such treatment, comprising local administration of antisecretory drugs and/or antacids, in acceptable pharmacological forms and pharmaceutical formulations.

The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata, a culture medium of Ceriporia lacerata hyphae including the extracellular polysaccharide, a composition for immunoregulation containing, as an active ingredient, dried powder of the hyphae culture medium or an extract of the hyphae culture medium, a pharmaceutical composition for preventing or treating an immune disease, and a health food for immunoregulation. The composition of the present invention has an excellent effect on immune enhancement and overactive immune response inhibition.

The present invention relates to a composition for treating or preventing an inflammatory skin disease, comprising, as an active ingredient, an unripe Citrus unshiu fruit extract and/or Synephrine or salt thereof. The composition of the present invention prevents an inflammatory reaction by inhibiting activity of STAT6, expression of eotaxin-1 and an agglomeration function of eosinophil, and thus, shows effects of preventing and treating an allergic inflammatory disease, atopic dermatitis, eczema, psoriasis, etc. Also, the composition of the present invention does not have cytotoxicity and a skin side effect, and thus, can be safely applied to pharmaceutical products and cosmetics.

The invention discloses a compound of the general formula (I) wherein X is selected from the group consisting of -(CH2)nOH, -(CH2)nNH2, -(CH2)nSH, -(CH2)mCOOH, -(CH2)mCOOR, -(CH2)mCONH2, -(CH2)m''CONH-OH, (CH2)m''CONH-R, and -(CH2)n'O(PO3)m''<(m''+1)>, wherein n=2, 3, 4 or 5; n'=2 or 3; m=1, 2, 3 or 4; m'=1, 2, 3, 4, 5 or 6; m''=1, 2 or 3; and R=-Cm'H2m'+1, or an aryl group, especially 1-[3,4-dihydroxy-5-(2-hydroxyethyl)-tetrahydrofuran-2-yl]pyrimidine-2,4(1H,3H)-dione, methods for treating or preventing MMP-related disorders and TNFalpha-related disorders alone or simultaneously, methods for the inhibition of the invasion and/or metastasis of ovarian carcinoma, and pharmaceutical compositions containing said compound for said treatments.

The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound is provided in the present invention as a class of novel CRL4^CRBN E3 ubiquitin ligase modulators in structure, wherein same has a stronger antitumor activity and antitumor spectrum, and can be used to prepare drugs for treating CRL4^CRBN E3 ligase-related diseases.

Disclosed is a pharmaceutical composition for preventing or treating nicotine addiction or withdrawal symptoms. The pharmaceutical composition includes miR-137 as an active ingredient. Overexpression of miR-137 in an animal model having nicotine addiction or withdrawal symptoms results in relief, prevention or amelioration of the symptoms. Therefore, the use of miR-137 contributes to the prevention or treatment of nicotine addiction or withdrawal symptoms and is expected to be useful for developing relevant therapeutic agents.

The invention is intended to provide a pharmaceutical composition for treating or preventing obesity or type II diabetes and a method for treatment for them. A pharmaceutical composition comprising an Acsl-1 inhibitor of this invention as an active ingredient is useful for prevention or treatment of obesity or type II diabetes.